Summary
Intuitive Surgical, Inc. (ISRG) filed its 2022 10-K report, detailing its continued growth in a dynamic global healthcare landscape. The company saw an 18% increase in da Vinci procedures, reaching approximately 1.875 million, alongside a substantial 218% rise in Ion system procedures to 23,500. This procedural growth drove a 13% increase in instruments and accessories revenue, highlighting the recurring revenue model's strength. However, systems revenue saw a slight 1% decrease, attributed to macroeconomic pressures, particularly in the U.S., which impacted hospital capital spending, and a 6% decline in da Vinci system placements. Despite these system placement challenges, the overall installed base of da Vinci systems grew by 12% to 7,544 units, indicating ongoing market penetration and adoption. The company's financial performance in 2022 showed total revenue growth of 9% to $6.2 billion, though operating income decreased by 13% to $1.58 billion, impacted by increased investments in R&D and SG&A expenses, including higher headcount and infrastructure costs. The gross profit margin also saw a slight decrease to 67.4% from 69.3% in the prior year, influenced by rising freight and material costs and unfavorable foreign currency impacts. Looking ahead, Intuitive Surgical faces ongoing risks related to macroeconomic conditions, supply chain constraints, and potential regulatory changes. The company is actively managing these challenges by focusing on innovation, expanding its product portfolio, and investing in its global infrastructure to support long-term growth and its mission of advancing minimally invasive care.
Financial Highlights
47 data points| Revenue | $6.22B |
| Cost of Revenue | $2.03B |
| Gross Profit | $4.20B |
| R&D Expenses | $879.00M |
| SG&A Expenses | $1.74B |
| Operating Expenses | $2.62B |
| Operating Income | $1.58B |
| Net Income | $1.32B |
| EPS (Basic) | $3.72 |
| EPS (Diluted) | $3.65 |
| Shares Outstanding (Basic) | 355.70M |
| Shares Outstanding (Diluted) | 362.00M |
Key Highlights
- 1Total revenue increased 9% year-over-year to $6.2 billion in 2022.
- 2da Vinci procedure volume grew 18% to approximately 1.875 million, while Ion procedure volume surged 218% to 23,500.
- 3Instruments and accessories revenue, a key recurring revenue stream, increased 13% to $3.52 billion.
- 4Systems revenue decreased 1% to $1.68 billion, with da Vinci system placements declining 6% year-over-year, reflecting macroeconomic pressures on hospital capital spending.
- 5The da Vinci installed base grew 12% to 7,544 systems, and the Ion installed base increased 149% to 321 systems.
- 6Gross profit margin decreased to 67.4% from 69.3% in 2021, impacted by increased costs and unfavorable foreign currency effects.
- 7Operating income decreased 13% to $1.58 billion due to increased operating expenses, particularly in R&D and SG&A, to support business growth.